Skip to main content
SpringerLink
Log in

Manage non-infectious uveitis in adults with individualized immunosuppressive therapy and regular monitoring

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The management of non-infectious uveitis in adults is challenging and requires precise and early diagnosis to allow prompt therapeutic intervention. While topical and/or systemic corticosteroids are mainstay options, some patients require timely treatment escalation with additional agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Airody A, Heath G, Lightman S, et al. Non-infectious uveitis: optimising the therapeutic response. Drugs. 2016;76(1):27–39.

    Article  CAS  PubMed  Google Scholar 

  2. Rothova A, Suttorp-van Shulten MX, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Deschenes J, Murray PI, Rao NA, et al. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2.

    Article  PubMed  Google Scholar 

  4. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.

    Article  PubMed  Google Scholar 

  5. Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121(1):365–76.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–95.

    Article  PubMed  Google Scholar 

  7. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Doycheva D, Zierhut M, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(8):1235–43.

    Article  CAS  PubMed  Google Scholar 

  9. Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–70.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pasadhika S, Kempen JH, Newcomb C, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32.

    Article  PubMed  Google Scholar 

  12. Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–84.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lee RW, Greenwood R, Taylor H, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119(6):1223–30.

    Article  PubMed  Google Scholar 

  14. Khan IJ, Barry RJ, Amissah-Arthur KN, et al. Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol. 2013;97(9):1118–22.

    Article  PubMed  Google Scholar 

  15. Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481–6.

    Article  PubMed  Google Scholar 

  16. Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892.e3–4.

  17. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87.

    Article  PubMed  Google Scholar 

  18. Tomkins-Netzer O, Taylor SR, Lightman S. Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica. 2013;230(3):109–15.

    Article  CAS  PubMed  Google Scholar 

  19. Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010;9(10):674–83.

    Article  CAS  PubMed  Google Scholar 

  20. Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–41.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53.

    Article  PubMed  Google Scholar 

  22. Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011;5:1613–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Cao JH, Mulvahill M, Zhang L, et al. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. 2014;121(10):1871–6.

    Article  PubMed  Google Scholar 

  24. Gulati N, Forooghian F, Lieberman R, et al. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol. 2011;95(2):162–5.

    Article  PubMed  Google Scholar 

  25. Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013;33(10):2149–54.

    Article  CAS  PubMed  Google Scholar 

  26. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013;3(1):32.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Dugel PU. Intravitreal sirolimus resolves inflammation in noninfectious intermediate or posterior uveitis: SAKURA study 1 [abstract]. In: American Academy of Ophthalmology meeting; 2015.

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Drugs 2016;76(1):27–39 [1] by salaried/contracted employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Manage non-infectious uveitis in adults with individualized immunosuppressive therapy and regular monitoring. Drugs Ther Perspect 32, 244–248 (2016). https://doi.org/10.1007/s40267-016-0304-7

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0304-7

    Keywords

    Search

    Navigation